Top

Documenta Ophthalmologica

Published in:

Open Access 01-06-2013 | Clinical Case Report

Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient

Authors: Marta Kiszkielis, Wojciech Lubiński, Krzysztof Penkala

Published in: Documenta Ophthalmologica | Issue 3/2013

Abstract

Purpose

The purpose of the study was to evaluate the efficacy of a topical form of a carbonic anhydrase inhibitor (dorzolamide) on the foveal function and thickness in the eye of a patient with enhanced S-cone syndrome (ESCS) associated with macular cysts.

Methods

Twenty-eight-year-old Polish man with ESCS and macular cysts appearance in the right eye was treated 3 times daily with 2.0 % dorzolamide drops for the period time equal to 6 months. Monthly controls included: best corrected distance visual acuity (BCDVA-logMAR), foveal thickness (optical coherence tomography, OCT) and foveal function (multi-focal electroretinography, mfERG).

Results

Before treatment, BCDVA in the right eye was equal to 0.26 logMAR, improved to 0.1 logMAR during the first 3 months and remained stable for the next 3 months. After 6 months, foveal thickness decreased (from 482 to 224 μm) and foveal function improved (the amplitude of P1-wave density increased from 34.8 to 107.3 nV/deg²) and was between the ranges of normal values. Implicit time of P1-wave remained prolonged.

Conclusions

The results of our short-term study suggest potential efficacy of topical dorzolamide treatment in ESCS patients with macular cysts.

Marmor MF, Jacobson SG, Foerster MH, Kellner U, Weleber RG (1990) Diagnostic clinical findings of a new syndrome with night blindness, maculopathy, and enhanced S cone sensitivity. Am J Ophthalmol 110(2):124–134PubMed

Haider NB, Jacobson SG, Cideciyan AV, Swiderski R, Streb LM, Searby C, Beck G, Hockey R, Hanna DB, Gorman S, Duhl D, Carmi R, Bennett J, Weleber RG, Fishman GA, Wright AF, Stone EM, Sheffield VC (2000) Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet 24(2):127–131PubMedCrossRef

Audo I, Michaelides M, Robson AG, Hawlina M, Vaclavik V, Sandbach JM, Neveu MM, Hogg CR, Hunt DM, Moore AT, Bird AC, Webster AR, Holder GE (2008) Phenotypic variation in enhanced S-cone syndrome. Invest Ophthalmol Vis Sci 49(5):2082–2093PubMedCrossRef

Sustar M, Hawlina M, Brecelj J (2011) Electroretinographic evaluation of the retinal S-cone system. Doc Ophthalmol 123(3):199–210PubMedCrossRef

Jacobson SG, Marmor MF, Kemp CM, Knighton RW (1990) SWS (blue) cone hypersensitivity in a newly identified retinal degeneration. Invest Ophthalmol Vis Sci 31(5):827–838PubMed

Ganesh A, Stroh E, Manayath GJ, Al-Zuhaibi S, Levin AV (2011) Macular cysts in retinal dystrophy. Curr Opin Ophthalmol 22(5):332–339PubMedCrossRef

Wolfensberger TJ (1999) The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 97(3–4):387–397PubMedCrossRef

Marmor MF, Maack T (1982) Enhancement of retinal adhesion and subretinal fluid resorption by acetazolamide. Invest Ophthalmol Vis Sci 23(1):121–124PubMed

Genead MA, Fishman GA, McAnany JJ (2010) Efficacy of topical dorzolamide for treatment of cystic macular lesions in a patient with enhanced S-cone syndrome. Doc Ophthalmol 121(3):231–240PubMedCrossRef

10.

Hajali M, Fishman GA (2009) Dorzolamide use in the management of macular cysts in a patient with enhanced S-cone syndrome. Retin Cases Brief Rep 3(2):121–124CrossRef

11.

Iannaccone A, Fung KH, Eyestone ME, Stone EM (2009) Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide. Am J Ophthalmol 147(2):307–312PubMedCrossRef

12.

Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M (2009) Standard for clinical electroretinography (2008 update). Doc Ophthalmol 118(1):69–77PubMedCrossRef

13.

Hood DC, Bach M, Brigell M, Keating D, Kondo M, Lyons JS (2012) ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol 124(1):1–13PubMedCrossRef

14.

Nagelhus EA, Mathiisen TM, Bateman AC, Haug FM, Ottersen OP, Grubb JH, Waheed A, Sly WS (2005) Carbonic anhydrase XIV is enriched in specific membrane domains of retinal pigment epithelium, muller cells, and astrocytes. Proc Natl Acad Sci USA 102(22):8030–8035PubMedCrossRef

15.

Ikeda Y, Hisatomi T, Yoshida N, Notomi S, Murakami Y, Enaida H, Ishibashi T (2012) The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 250(6):809–814PubMedCrossRef

16.

Apushkin MA, Fishman GA, Grover S, Janowicz MJ (2007) Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina 27(8):1112–1118PubMedCrossRef

17.

Fishman GA, Apushkin MA (2007) Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 91(6):743–745PubMedCrossRef

18.

Grover S, Apushkin MA, Fishman GA (2006) Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 141(5):850–858PubMedCrossRef

19.

Genead MA, McAnany JJ, Fishman GA (2012) Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia. Retina 32(4):826–833PubMedCrossRef

20.

Khandhadia S, Trump D, Menon G, Lotery AJ (2011) X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype. Eye (Lond) 25(7):922–928CrossRef

21.

Hood DC, Frishman LJ, Saszik S, Viswanathan S (2002) Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci 43:1673–1685PubMed

22.

Hwang JU, Sohn J, Moon BG, Joe SG, Lee JY, Kim JG, Yoon YH (2012) Assessment of macular function for idiopathic epiretinal membranes classified by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 53(7):3562–3569PubMedCrossRef

23.

Wen Y, Klein M, Hood DC, Birch DG (2012) Relationships among multifocal electroretinogram amplitude, visual field sensitivity, and SD-OCT receptor layer thicknesses in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci 53(2):833–840PubMedCrossRef

24.

Georgiadou E, Moschos MM, Margetis I, Chalkiadakis J, Markomichelakis NN (2012) Structural and functional outcomes after treatment of uveitic macular oedema: an optical coherence tomography and multifocal electroretinogram study. Clin Exp Optom 95(1):89–93PubMedCrossRef

Title: Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient
Authors: Marta Kiszkielis
Wojciech Lubiński
Krzysztof Penkala
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Documenta Ophthalmologica / Issue 3/2013
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI: https://doi.org/10.1007/s10633-012-9371-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

Evaluation of structural and functional changes in non-pathologic myopic fundus using multifocal electroretinogram and optical coherence tomography

Phenotypic characterization of a Chinese family with autosomal dominant cone–rod dystrophy related to GUCY2D

Erratum to: Can we do without mydriasis in multifocal ERG recordings?

Functional protective effects of long-term memantine treatment in the DBA/2J mouse

Decreased retinal–choroidal blood flow in retinitis pigmentosa as measured by MRI

Spectral domain optical coherence tomography findings in bilateral peripheral cone dystrophy